NCT00954057 is a Phase 2 clinical trial of LIPO-102 in Thyroid-Related Eye Disease, sponsored by Neothetics, Inc.

Who is sponsoring NCT00954057?

NCT00954057 is sponsored by Neothetics, Inc.

What drugs are being tested in NCT00954057?

Interventions in NCT00954057: LIPO-102, Placebo.

What condition does NCT00954057 study?

NCT00954057 studies Thyroid-Related Eye Disease.

Is NCT00954057 still recruiting?

NCT00954057 is currently completed. Last updated 5 March 2015.

Last reviewed 2015-03-05 · How we verify

NCT00954057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-masked, Placebo Controlled, Multi-center Pilot Study to Determine the Safety and Efficacy of Orbital Injections of a Fixed Dose of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease

Completed Phase 2 Last updated 5 March 2015

What this trial tests

Phase 2 trial testing LIPO-102 in Thyroid-Related Eye Disease in 11 participants. Completed in 1 June 2011.

Timeline

1 September 2009

Primary endpoint
1 June 2011

1 June 2011

Quick facts

Lead sponsor	Neothetics, Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	11
Start date	1 September 2009
Primary completion	1 June 2011
Estimated completion	1 June 2011
Sites	5 locations across Australia, New Zealand

Drugs / interventions tested

LIPO-102 — full drug profile →
Placebo

Conditions studied

Thyroid-Related Eye Disease — all drugs for Thyroid-Related Eye Disease →

Sponsor

Neothetics, Inc — full company profile →

Who can join

Adults 18 to 65, any sex, with Thyroid-Related Eye Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety: physical examinations, laboratory tests, VISA activity score, AE assessments
Time frame: 8 weeks treatment and 1 week follow up

Sponsor's own description

This is a pilot study to determine the safety and efficacy of orbital injections of LIPO-102.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Neothetics, Inc trials

Trials by the same sponsor.

NCT03005717 — Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00954057 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neothetics, Inc
Last refreshed: 5 March 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00954057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing